Learn about the emotional impact of chronic monitoring in acromegaly, signs of treatment fatigue, and strategies for managing ...

Crinetics Pharmaceuticals explores rare endocrine treatments, PALSONIFY development, biotechnology operations, and healthcare innovation within the Nasdaq Composite market environment.

Vertex Pharma has made the largest acquisition in its history, agreeing to buy Crinetics Pharma for around $10 billion in a ...

This buy gives Vertex both a recently-commercialized drug, and a very strong lead candidate.

With expected close this quarter, the stock should converge toward the deal price as deal certainty rises and spreads tighten ...

Vertex Pharmaceuticals will acquire Crinetics Pharmaceuticals for $10 billion at $85 per share, adding the approved drug ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global ...

Transaction terms include $85-per-share all-cash consideration (~$10B enterprise value) and an anticipated Q3 2026 close, contingent on customary conditions. Portfolio fit emphasizes serious, ...

Vertex Pharmaceuticals Incorporated’s $10B Crinetics Pharmaceuticals, Inc. buy adds PALSONIFY & a Phase 3 CAH asset. Click ...

Vertex Pharma to buy Crinetics Pharmaceuticals for $10 billion: Boston Wednesday, July 8, 2026, 14:00 Hrs [IST] Vertex Pharmaceuticals Incorporated, a global biotechnology company ...

Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals for $10 billion cash, in a deal that would expand the ...

M&A activity in global healthcare is picking up and ASX stocks could be a target as Big Pharma looks to replace drugs coming ...